UT-MD Anderson Cancer Center: ESMO - Erdafitinib Demonstrates Improved Responses in FGFR-Altered Advanced Urinary Tract Cancers
October 23, 2023
October 23, 2023
HOUSTON, Texas, Oct. 23 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
MD Anderson-led study shows benefits over chemotherapy for patients previously treated with immunotherapy
* * *
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib improved responses and overall survival compared to standard chemotherapy for patients with metastatic urothelial ca . . .
* * *
MD Anderson-led study shows benefits over chemotherapy for patients previously treated with immunotherapy
* * *
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib improved responses and overall survival compared to standard chemotherapy for patients with metastatic urothelial ca . . .